ToplineTwo of the nation’s most influential health systems have said they won’t administer Biogen’s Aduhelm, a controversial new Alzheimer’s treatment approved by the Food and Drug Administration last month, as concerns have grown about conflicting evidence about Aduhelm’s efficacy from clinical trials. Peter Bristol of Wakefield, Rhode Island, receives an intravenous infusion at Butler Hospital in ... [+] Providence in 2014, part of a study for another Alzheimer's treatment. Biogen must hold confirmatory trials, and if the studies don’t show clinical benefits from taking the drug, Aduhelm may be pulled from the market. The decision proved to be controversial, and some experts spoke out against the approval over conflicting data from clinical trials about the efficacy of the drug. Further ReadingFDA Approves First New Drug To Treat Alzheimer’s Disease In Nearly 20 Years (Forbes)FDA Reverses Broad Approval For Controversial Alzheimer’s Drug (Forbes)

Source: Forbes July 15, 2021 19:18 UTC